In This Section

Program

Please note that this meeting will take place as an in-person event in San Diego, California and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

SUNDAY, JANUARY 26

MONDAY, JANUARY 27

TUESDAY, JANUARY 28

WEDNESDAY, JANUARY 29

Sunday, January 26

REGISTRATION

2:30-7 p.m. | Sapphire North Foyer

WELCOME AND OPENING Keynote

6:15-6:20 p.m. | Sapphire MN | CME Eligible

  • Introduction of keynote speaker
    Quynh-Thu Le, Stanford Cancer Institute, Stanford, California

6:15-7 p.m. | CME Eligible

  • Michael Baumann, DFKZ German Cancer Research Center, Heidelberg, Germany 

Opening Reception

7-9 p.m. | Sapphire Terrace

Monday, January 27

CONTINENTAL BREAKFAST

7-8 a.m. | Sapphire EFIJ

Plenary Session 1: FLASH

8-10 a.m. | Sapphire MN | CME Eligible

Session Chair: Marie-Catherine Vozenin, Lausanne University Hospital, Lausanne, Switzerland 

  • 8 a.m. | FLASH, an opportunity for the treatment of pediatric brain tumors or Transcriptional imprint of FLASH radiotherapy 
    Marie-Catherine Vozenin, Lausanne University Hospital, Lausanne, Switzerland 
  • 8:25 a.m. | FLASH radiotherapy enhances immune activation and spares lymphocytes tumor draining lymph nodes*
    Michael Spiotto, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 8:35 a.m. | Proton FLASH radiotherapy: How lessons from preclinical models inform clinical trials 
    Constantinos Koumenis, University of Pennsylvania, Philadelphia, Pennsylvania
  • 9 a.m. | Discovery and validation of mTOR as an immune mediator of the FLASH effect*
    Danielle P. Johnson Erickson, University of Washington Department of Radiation Oncology, Seattle, Washington
  • 9:10 a.m. | FLASH—where are we and where are we going in the clinical trial future space
    Jeffery C. Buchsbaum, National Cancer Institute, Rockville, Maryland

BREAK

9:35-10 a.m. | Sapphire North Foyer

Proffered Talks  

10 a.m.-10:50 a.m. | Sapphire MN | CME Eligible

Session Chair: Jeffery C. Buchsbaum, National Cancer Institute, Rockville, Maryland

In honor of Dr. C. Norman Coleman

  • 10:00 a.m. | Phase III randomized trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the management of head and neck oropharyngeal cancer*
    Steven Frank, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 10:10 a.m. | Spatiometabolic mapping of cytoarchitectural changes in lung adenocarcinoma following radiotherapy*
    Gina Bouchard, University of Colorado Anschutz Medical Campus, Boulder, Colorado
  • 10:20 a.m. | Mapping cellular and microenvironmental determinants of persisterpopulations in pancreatic cancer following neoadjuvant chemoradiation*
    Vincent Bernard, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 10:30 a.m. | Investigating the role of the tumor microenvironment in the rectal cancer response to preclinical radio-immunotherapy combinations*
    Lydia Melissourgou-Syka, CRUK Scotland Institute for Cancer Research, Glasgow, Scotland
  • 10:40 a.m. | Countering adenosine (ADO) in rectal cancer to improve RT responses to immune checkpoint blockade: Trial to test the safety and efficacy of PD1 (AB122) and ADO dual receptor (AB928) antagonists with chemotherapy after short-course RT*
    Encouse Golden, Weill Cornell Medicine, New York, New York

Break

10:50-11:10 a.m. | Sapphire North Foyer

Plenary Session 2: Nodal management with immune checkpoint therapy 

11:10 a.m. –12:45 p.m. | Sapphire MN | CME Eligible

Session Chair: Sana D. Karam, Washington University School of Medicine, St. Louis, Missouri

  • 11:10 a.m. | To treat or not to treat: Nodal irradiation in the context of immunotherapy
    Sana D. Karam, Washington University School of Medicine, St. Louis, Missouri
  • 11:35 a.m. | Harnessing macrophage plasticity and radiotherapy for breast cancer immunotherapy*
    Nir Ben Chetrit, Weill Cornell Medicine, New York, New York
  • 11:45 a.m. | Preserving tumor-draining lymph nodes in the era of immuno-oncology: Opportunities for precision chemo-radio-immunotherapy
    J. Silvio Gutkind, University of California, San Diego, San Diego, California 
  • 12:10- 12:20 p.m. | Mapping the tumor-sentinel node immune migratome demonstrates a  key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy*
    Robert Saddawi-Konefka, University of California San Diego, San Diego, California
  • 12:20 p.m. | Tumor draining lymph nodes: Friends or Foes
    Quynh-Thu Le, Stanford Cancer Institute, Stanford, California

Lunch on own

12:45-2:30 p.m.

Plenary Session 3: Theragnostics and external beam 

2:30-4:05 p.m. | Sapphire MN | CME Eligible

Session Chair: Rebecca K.S. Wong, UHN Princess Margaret Cancer Center, Toronto, ON, Canada

  • 2:30 p.m. | Chemical strategies to expand the therapeutic window of targeted radiotherapies
    Michael Evans, University of California San Francisco, San Francisco, California
  • 2:55 p.m. | Partial tumor volume irradiation by 177 Lu-PNT6555 induces diverse immune responses in a syngeneic murine tumor model*
    Maya E. Takashima, University of Wisconsin – Madison, Madison, Wisconsin
  • 3:05 p.m. | Rebecca K.S. Wong, UHN Princess Margaret Cancer Center, Toronto, ON, Canada
  • 3:30 p.m. | Fibroblast Activation Protein (FAP)-targeted radioligand therapy as a  promising treatment for glioblastoma*
    Ines Camille Azrour, University of California Los Angeles, Los Angeles, California
  • 3:40 p.m. | Opportunities and approaches for combining theranostics and other forms of radiation therapy for cancer
    Zachary Morris, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Lightning Talks A

4:05- 4:10 p.m. | Sapphire MN | CME Eligible

  • A novel PARP inhibitor PET tracer: Implications for theranostics
    Lilie Lin, University of Texas, MD Anderson Cancer Center, Houston, Texas
  • Activity of antibody-drug conjugates with radiation in preclinical bladder cancer models
    Kent Mouw, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, Massachusetts

Poster Session A and Reception

4:10-5:40 p.m. | Sapphire EFIJ

Tuesday, January 28

CONTINENTAL BREAKFAST

7-8 a.m. | Sapphire EFIJ

Plenary Session 4: AI in radiation therapy

8-9:35 a.m. | Sapphire MN | CME Eligible

  • 8 a.m. | Personalized oncology, adaptive radiotherapy, and AI agents
    Steven B. Jiang, UT Southwestern, Dallas, Texas
  • 8:25 a.m. | A digital pathology multimodal artificial intelligence algorithm is associated with pro-metastatic genomic pathways in oligometastatic prostate cancer*
    Matthew P. Deek, Rutgers Cancer Institute, Rutgers, New Jersey
  • 8:35 a.m. | Evaluating and mitigating medical misinformation risk in large language models
    Danielle S. Bitterman, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 9 a.m. | Evaluating associations between genomic classifier and digital pathology based mutli-modal AI biomarkers in oligometastatic castration-sensitive prostate cancer*
    Philip A. Sutera, University of Rochester, Rochester, New York
  • 9:10 a.m. | Toward multi-modal foundation AI for precision oncology
    Ruijiang Li, Stanford University, Stanford, California

BREAK

9:35-10 a.m. | Sapphire North Foyer

Plenary Session 5: Ferroptosis and radiation 

10-11:35 a.m. | Sapphire MN | CME Eligible

Session Chair: Albert C. Koong, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 10 a.m. | Targeting ferroptosis in radioresistance 
    Boyi Gan, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 10:25 a.m. | Gadolinium-based nanoparticles sensitize ovarian peritoneal carcinomatosis to targeted radionuclide therapy*
    Clara Diaz Garcia-Prada, University of California Los Angeles, Los Angeles, California
  • 10:35 a.m. | Understanding ferroptosis molecular mechanisms to advance ferroptosis therapies in cancer 
    Scott Dixon, Stanford University, Stanford, California
  • 11 a.m. | Monitoring cancer ferroptosis with [18F] hGTS13, a system xc- specific radiotracer*
    Abraham Moses, Stanford University, Stanford, California
  • 11:10 a.m. | Immune side effects in ferroptosis-targeted therapy
    Daolin Tang, UT Southwestern Medical Center, Dallas, Texas

Lunch on own

11:35 a.m.-1 p.m.

Spotlight Session: Industry perspectives on integrating radiation therapy with pharmaceutical treatments

1-2 p.m. | Sapphire MN | Not CME-eligible

  • Swati Ghirdhani, IBA Proton Therapy, Herndon, Virginia
  • Karine Al Feghali, RefleXion, Hayward, California
  • Sailaja Battula, Ankyra Therapeutics, Cambridge, Massachusetts

Break

2-2:30 p.m. | Sapphire North Foyer

Plenary Session 6: Integrating DNA damage repair targeting with radiation therapy

Session Chair: Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York

2:30-4:05 p.m. | Sapphire MN | CME Eligible

  • 2:30 p.m. | Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2:55 p.m. | PSMA-RLT and targeting the cGAS-STING pathway as a combination approach for prostate cancer*
    Beatrice Louis, University of California at Los Angeles, Los Angeles, California
  • 3:05 p.m. | Enhancing radiation-induced anti-tumoral immune responses with PARP inhibitors in PDAC and DIPG
    Meredith A. Morgan, University of Michigan, Ann Arbor, Michigan
  • 3:30 p.m. | STN1 (OBFC1) promotes DNA double-strand break repair in a potentially CTC1-STN1-TEN1 (CST) complex-independent role in pancreatic cancer*
    Tiantian Cui, City of Hope National Medical Center, Duarte, California
  • 3:40 p.m. | Vulnerabilities of pathologic DNA damage responses
    Gaorav P. Gupta, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Break

4:05-4:24 p.m. | Sapphire North Foyer

Plenary Session 7: Role of radiation and cell therapy 

4:25-6 p.m. | Sapphire MN | CME Eligible

  • 4:25 p.m. | Low-dose total body irradiation improves response to CAR T cell therapy 
    Monica L. Guzman, Weill Cornell Medical College, New York, New York
  • 4:50 p.m. | Sparing blood and immune rich organs significantly reduces immune suppression during lung SBRT: Randomized, phase 2 trial*
    Krishni Wijesooriya, University of Virginia, Richmond, Virginia
  • 5 p.m. | Radiation of hematological malignancies: insights into sublethal dosing and salvage immune therapies enhancement
    Joachim Yahalom, Memorial Sloan Kettering Cancer Center, New York, New York
  • 5:25 p.m. | Low-dose radiation acts as a promising preconditioning regimen for dendritic cell vaccines*
    Eric Kwon, Washington University in Saint Louis School of Medicine, St. Louis, Missouri
  • 5:35 p.m. | NK-Cell based CAR Therapy: Current status and future directions
    Hind Rafei, The University of Texas MD Anderson Cancer Center, Houston, Texas

Lightning Talks B

6-6:15 p.m. | Sapphire MN | CME Eligible

  • Targeting the angiotensin receptor in cancer-associated fibroblasts improves tumor perfusion, oxygenation, and radiotherapy response
    Kevin Bennewith, BC Cancer Research Institute, Vancouver, Canada
  • Pre-vaccine radiation and CTLA-4 blockade increase adjuvant effects of SARS-COV-2 mRNA vaccines
    Adam Grippin, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Systematic analysis of tumor and immune EV subset changes with radiation therapy
    Jennifer Jones, NIH, Bethesda, Maryland
  • CD163+ tumor-associated macrophage evasion contributes radiation resistance and poor prognosis in estrogen receptor-negative breast cancer
    Danushka S. Seneviratne, Oklahoma University Health Science Center, Oklahoma City, Oklahoma
  • Dual checkpoint blockade mitigates the immunosuppressive effects of radiotherapy amplified by experimental liver metastasis
    Han Zang, University of California San Francisco, San Francisco, California

Poster Session B and Reception  

6:15-7:45 p.m. | Sapphire EFIJ

Wednesday, January 29

CONTINENTAL BREAKFAST

7-8 a.m. | Sapphire EFIJ

Plenary Session 8: Update on radiation and immunotherapy

8-9:35 a.m. | Sapphire MN | CME Eligible

Session Chair: Silvia C. Formenti, Weill Cornell Medicine, New York, New York

  • 8 a.m. | David G. Kirsch, UHN Princess Margaret Cancer Center, Toronto, Canada 
  • 8:25 a.m. | Optimizing macrophage-mediated abscopal effects for enhanced clinical translation: Radiation therapy combined with CD47 blockade*
    Yoko Nishiga, Stanford University, Stanford, California
  • 8:35 a.m. | Preliminary results of a multicentric, prospective randomized trial testing focal radiotherapy and immunotherapy in HR+ breast cancer patients
    Silvia C. Formenti, Weill Cornell Medicine, New York, New York
  • 9 a.m. | Targeting SPP1 to enhance CAR T cell therapy in glioblastoma: Implications for integrating radiation therapy in resistant solid tumors*
    Sharareh Gholamin, City of Hope, Duarte, California                                    
  • 9:10 a.m. | Andy J. Minn, University of Pennsylvania, Philadelphia, Pennsylvania

BREAK

9:35-10 a.m. | Sapphire North Foyer

KEynote

10-11:15 a.m. | Sapphire MN | CME Eligible

  • 10 a.m. | Introduction of keynote speaker
    Albert C. Koong, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 10:05 a.m. | Radiotherapy immunotherapy interactions: Determinants of success and failure
    Ralph R. Weichselbaum, University of Chicago, Chicago, Illinois

Plenary Session 9: Emerging therapeutics or biomarkers for radiation therapy  

10:45 a.m.-12:10 p.m. | Sapphire MN | CME Eligible

Session Chair: Quynh-Thu Le, Stanford Cancer Institute, Stanford, California

  • 10:45 a.m. | Liquid biopsies for noninvasive detection and characterization of cancers
    Maximillian Diehn, Stanford University, Stanford, California     
  • 11:10 a.m. | Albert C. Koong, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 11:35 a.m. | Circulating tumor DNA kinetics identify prodynorphin signaling as a target to radiosensitize non-small cell lung cancer*
    Ziwei Wang, Stanford University, Stanford, California
  • 11:45 a.m. | Therapeutic strategies and biomarker approaches for chromosomal instability
    Samuel F. Bakhoum, Volastra Therapeutics, New York, New York

Closing Remarks and Departure

12:10 p.m. | Sapphire MN